Trial Profile
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure; Heart failure
- Focus Biomarker; Therapeutic Use
- Acronyms PROVE-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Dec 2022 Results published in the Journal of Cardiac Failure
- 03 Nov 2022 Results assessing the changes in B-type natriuretic peptide following neprilysin inhibition as measured by 3 immunoassays that recognize different epitopes, published in the Clinical Chemistry.
- 31 Aug 2022 According to a The Heart Failure Society of America media release, results from this trial will be presented at the The Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), which will take place September 30 - October 3, 2022.